Cubist Pharmaceuticals Makes Three Executive Appointments
Cubist Pharmaceuticals Inc. (Cambridge, Mass.) announced that Dennis Keith, Ph.D. has been hired to the post of vice president, drug discovery. Francis Tally, M.D., who previously held this position, has been promoted to executive vice president, scientific affairs. The company also announced the election of David Martin, Jr., M.D to the company's board of directors.
"Dr. Keith brings a very impressive background in anti-infective drug discovery to Cubist Pharmaceuticals. Dr. Keith's more than 25 years of pharmaceutical industry experience in drug discovery combined with Francis Tally's research and clinical medical experience will be instrumental to Cubist as we move from a target discovery company to a drug development company," said Scott Rocklage, Ph.D., President and CEO of Cubist. "We also welcome Dr. Martin and his broad industry experience to our board of directors."
Keith spent the last 26 years as a member of the Research and Development team at Hoffmann-LaRoche where he began his career in 1971. Prior to joining Cubist, Keith was senior director and research director of oncology, a position he held since 1992; senior director of medicinal chemistry; and director of the department of anti-infective chemistry. Keith received his Ph.D. in organic chemistry from Yale and was a recipient of a fellowship from the National Institute of Health. Keith completed his post-doctoral fellowship in the laboratory of Professor R.B. Woodward at Harvard University.
Martin has held senior executive positions at Genentech, Inc., E.I. du Pont de Nemours & Co., Inc., and The DuPont Merck Pharmaceutical Co., and was most recently President, CEO and Director of Lynx Therapeutics, Inc. He presently maintains the position of adjunct professor of medicine and biochemistry at the University of California, San Francisco. Martin received his M.D. from Duke University.
Cubist Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel antibiotic and antifungal drugs to combat emerging strains of drug resistant bacteria and fungi.